132 related articles for article (PubMed ID: 12758149)
1. Recombinant human C1-inhibitor produced in Pichia pastoris has the same inhibitory capacity as plasma C1-inhibitor.
Bos IG; de Bruin EC; Karuntu YA; Modderman PW; Eldering E; Hack CE
Biochim Biophys Acta; 2003 May; 1648(1-2):75-83. PubMed ID: 12758149
[TBL] [Abstract][Full Text] [Related]
2. The functional integrity of the serpin domain of C1-inhibitor depends on the unique N-terminal domain, as revealed by a pathological mutant.
Bos IG; Lubbers YT; Roem D; Abrahams JP; Hack CE; Eldering E
J Biol Chem; 2003 Aug; 278(32):29463-70. PubMed ID: 12773530
[TBL] [Abstract][Full Text] [Related]
3. Recombinant C1 inhibitor in brain ischemic injury.
Gesuete R; Storini C; Fantin A; Stravalaci M; Zanier ER; Orsini F; Vietsch H; Mannesse ML; Ziere B; Gobbi M; De Simoni MG
Ann Neurol; 2009 Sep; 66(3):332-42. PubMed ID: 19798727
[TBL] [Abstract][Full Text] [Related]
4. The potentiation of human C1-inhibitor by dextran sulphate is transient in vivo: studies in a rat model.
Bos IG; van Mierlo GJ; Bleeker WK; Rigter GM; te Velthuis H; Dickneite G; Hack CE
Int Immunopharmacol; 2001 Aug; 1(8):1583-95. PubMed ID: 11515821
[TBL] [Abstract][Full Text] [Related]
5. Pathogenic mechanisms of bradykinin mediated diseases: dysregulation of an innate inflammatory pathway.
Kaplan AP; Joseph K
Adv Immunol; 2014; 121():41-89. PubMed ID: 24388213
[TBL] [Abstract][Full Text] [Related]
6. Polyphosphate is a novel cofactor for regulation of complement by a serpin, C1 inhibitor.
Wijeyewickrema LC; Lameignere E; Hor L; Duncan RC; Shiba T; Travers RJ; Kapopara PR; Lei V; Smith SA; Kim H; Morrissey JH; Pike RN; Conway EM
Blood; 2016 Sep; 128(13):1766-76. PubMed ID: 27338096
[TBL] [Abstract][Full Text] [Related]
7. Expression of active human C1 inhibitor serpin domain in Escherichia coli.
Lamark T; Ingebrigtsen M; Bjørnstad C; Melkko T; Mollnes TE; Nielsen EW
Protein Expr Purif; 2001 Jul; 22(2):349-58. PubMed ID: 11437612
[TBL] [Abstract][Full Text] [Related]
8. Serpins and the complement system.
Beinrohr L; Murray-Rust TA; Dyksterhuis L; Závodszky P; Gál P; Pike RN; Wijeyewickrema LC
Methods Enzymol; 2011; 499():55-75. PubMed ID: 21683249
[TBL] [Abstract][Full Text] [Related]
9. Citrullination of C1-inhibitor as a mechanism of impaired complement regulation in rheumatoid arthritis.
Martin M; Nilsson SC; Eikrem D; Fromell K; Scavenius C; Vogt LM; Bielecka E; Potempa J; Enghild JJ; Nilsson B; Ekdahl KN; Kapetanovic MC; Blom AM
Front Immunol; 2023; 14():1203506. PubMed ID: 37426666
[TBL] [Abstract][Full Text] [Related]
10. C1-inhibitor polymers activate the FXII-dependent kallikrein-kinin system: Implication for a role in hereditary angioedema.
Madsen DE; Sidelmann JJ; Biltoft D; Gram J; Hansen S
Biochim Biophys Acta; 2015 Jun; 1850(6):1336-42. PubMed ID: 25800206
[TBL] [Abstract][Full Text] [Related]
11. Recombinant human C1 esterase inhibitor in the management of hereditary angioedema.
Riedl M
Clin Drug Investig; 2015 Jul; 35(7):407-17. PubMed ID: 26091744
[TBL] [Abstract][Full Text] [Related]
12. Effects of C1 inhibitor on tissue damage in a porcine model of controlled hemorrhage.
Dalle Lucca JJ; Li Y; Simovic M; Pusateri AE; Falabella M; Dubick MA; Tsokos GC
Shock; 2012 Jul; 38(1):82-91. PubMed ID: 22683724
[TBL] [Abstract][Full Text] [Related]
13. Hereditary and acquired deficiencies of C1 inhibitor.
Davis AE
Immunodefic Rev; 1989; 1(3):207-26. PubMed ID: 2698641
[TBL] [Abstract][Full Text] [Related]
14. Structure and function of C1 inhibitor.
Davis AE
Behring Inst Mitt; 1989 Jul; (84):142-50. PubMed ID: 2679529
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of recombinant human C1-inhibitor for the treatment of attacks of hereditary angioedema: European open-label extension study.
Moldovan D; Reshef A; Fabiani J; Kivity S; Toubi E; Shlesinger M; Triggiani M; Montinaro V; Cillari E; Realdi G; Cancian M; Visscher S; Zanichelli A; Relan A; Cicardi M
Clin Exp Allergy; 2012 Jun; 42(6):929-35. PubMed ID: 22909164
[TBL] [Abstract][Full Text] [Related]
16. Effect of reactive site loop elongation on the inhibitory activity of C1-inhibitor.
Bos IG; Lubbers YT; Eldering E; Abrahams JP; Hack CE
Biochim Biophys Acta; 2004 Jun; 1699(1-2):139-44. PubMed ID: 15158721
[TBL] [Abstract][Full Text] [Related]
17. Structural and functional aspects of C1-inhibitor.
Bos IG; Hack CE; Abrahams JP
Immunobiology; 2002 Sep; 205(4-5):518-33. PubMed ID: 12396012
[TBL] [Abstract][Full Text] [Related]
18. C1 inhibitor: molecular and clinical aspects.
Cicardi M; Zingale L; Zanichelli A; Pappalardo E; Cicardi B
Springer Semin Immunopathol; 2005 Nov; 27(3):286-98. PubMed ID: 16267649
[TBL] [Abstract][Full Text] [Related]
19. C1-Esterase inhibitor: an anti-inflammatory agent and its potential use in the treatment of diseases other than hereditary angioedema.
Caliezi C; Wuillemin WA; Zeerleder S; Redondo M; Eisele B; Hack CE
Pharmacol Rev; 2000 Mar; 52(1):91-112. PubMed ID: 10699156
[TBL] [Abstract][Full Text] [Related]
20. Recombinant Human C1 Esterase Inhibitor for the Management of Adverse Events Related to Intravenous Immunoglobulin Infusion in Patients With Common Variable Immunodeficiency or Polyneuropathy: A Pilot Open-Label Study.
Melamed IR; Miranda H; Heffron M; Harper JR
Front Immunol; 2021; 12():632744. PubMed ID: 33737935
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
